Relationship between target organ damage and blood pressure, retinal vessel calibre, oxidative stress and polymorphisms in VAV-2 and VAV-3 genes in patients with hypertension: a case-control study protocol (LOD-Hipertension)

Manuel A Gomez-Marcos, Rogelio Gonzalez-Sarmiento, José I Recio-Rodríguez, Cristina Agudo-Conde, Luis Gamella-Pozuelo, Nuria Perretta-Tejedor, Carlos Martínez-Salgado, Luis García-Ortiz, Members of the LOD-Hipertensión Group, Maria C Patino-Alonso, Leticia Gómez-Sánchez, Emiliano Rodriguez-Sanchez, Carmela Rodriguez-Martín, Carmen Castaño-Sanchez, Angela de Cabo-Laso, Benigna Sanchez-Salgado, Marta Gómez-Sánchez, Manuel A Gomez-Marcos, Rogelio Gonzalez-Sarmiento, José I Recio-Rodríguez, Cristina Agudo-Conde, Luis Gamella-Pozuelo, Nuria Perretta-Tejedor, Carlos Martínez-Salgado, Luis García-Ortiz, Members of the LOD-Hipertensión Group, Maria C Patino-Alonso, Leticia Gómez-Sánchez, Emiliano Rodriguez-Sanchez, Carmela Rodriguez-Martín, Carmen Castaño-Sanchez, Angela de Cabo-Laso, Benigna Sanchez-Salgado, Marta Gómez-Sánchez

Abstract

Introduction: Target organ damage (TOD) is associated with increased cardiovascular risk. The study objectives were to analyse the relationship of TOD to blood pressure, size of retinal arteries and veins, oxidative stress and different polymorphisms in the VAV-2 and VAV-3 genes in participants with hypertension.

Methods and analysis: A case-control study to analyse the relationship between clinical, biochemical and genetic parameters and presence of cardiac, vascular and renal TOD in 486 patients with hypertension. Participants with TOD will be considered as cases, and those without TOD will be enrolled as controls. This will be a collaborative study conducted by the groups of Primary Care, Cardiovascular and Metabolic and Degenerative Diseases of the Instituto de Investigación Biomédica of Salamanca (IBSAL). Assessment of cardiac, renal and vascular TOD. Measurement of peripheral and central blood pressure, size of eye fundus arteries and veins, and oxidative stress, and polymorphisms in the VAV-2 and VAV-3 genes.

Ethics and dissemination: The study will be conducted after approval is obtained from the Ethics Committee of Hospital Clínico Universitario of Salamanca. All study participants will sign an informed consent to agree to participate in the study, and another consent to agree on the genetic study, in compliance with the Declaration of Helsinki and the WHO standards for observational studies. The results of this study will allow for an understanding of the relationship of the different TODs with blood pressure, retinal artery and vein diameters, oxidative stress and polymorphisms in VAV-2 and VAV-3 genes.

Trial registration number: Clinical Trials. gov Identifier: NCT02022618.

Keywords: Blood pressure; Oxidative stress; Polymorphisms.; Retinal arteries and veins; Target organ damage.

References

    1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–13
    1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281–357
    1. Li Z, Dahlof B, Okin PM, et al. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan intervention for endpoint reduction in hypertension study. J Hypertens 2008;26:1244–9
    1. Havranek EP, Froshaug DB, Emserman CD, et al. Left ventricular hypertrophy and cardiovascular mortality by race and ethnicity. Am J Med 2008;121:870–5
    1. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813–21
    1. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285–95
    1. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007;115:459–67
    1. Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004;109:733–9
    1. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213–25
    1. Peters SA, den Ruijter HM, Bots ML, et al. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart 2012;98:177–84
    1. Kikuya M, Ohkubo T, Asayama K, et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. Hypertension 2005;45:240–5
    1. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005;111:1777–83
    1. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005;46:156–61
    1. Ward AM, Takahashi O, Stevens R, et al. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens 2012;30:449–56
    1. Stergiou GS, Argyraki KK, Moyssakis I, et al. Home blood pressure is as reliable as ambulatory blood pressure in predicting target-organ damage in hypertension. Am J Hypertens 2007;20:616–21
    1. Gaborieau V, Delarche N, Gosse P. Ambulatory blood pressure monitoring versus self-measurement of blood pressure at home: correlation with target organ damage. J Hypertens 2008;26:1919–27
    1. Bliziotis IA, Destounis A, Stergiou GS. Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis. J Hypertens 2012;30:1289–99
    1. Dolan E, Thijs L, Li Y, et al. Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension 2006;47:365–70
    1. Kikuya M, Staessen JA, Ohkubo T, et al. Ambulatory arterial stiffness index and 24-hour ambulatory pulse pressure as predictors of mortality in Ohasama, Japan. Stroke 2007;38:1161–6
    1. Vasunta RL, Kesaniemi YA, Ylitalo A, et al. Nondipping pattern and carotid atherosclerosis in a middle-aged population: OPERA Study. Am J Hypertens 2012;25:60–6
    1. Kotsis V, Stabouli S, Karafillis I, et al. Arterial stiffness and 24 h ambulatory blood pressure monitoring in young healthy volunteers: the early vascular ageing Aristotle University Thessaloniki Study (EVA-ARIS Study). Atherosclerosis 2011;219:194–9
    1. Mancia G. Short- and long-term blood pressure variability: present and future. Hypertension 2012;60:512–17
    1. Verdecchia P, Angeli F, Mazzotta G, et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension 2012;60:34–42
    1. Pini R, Cavallini MC, Palmieri V, et al. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol 2008;51:2432–9
    1. Roman MJ, Okin PM, Kizer JR, et al. Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study. J Hypertens 2010;28:384–8
    1. DeLoach SS, Appel LJ, Chen J, et al. Aortic pulse pressure is associated with carotid IMT in chronic kidney disease: report from Chronic Renal Insufficiency Cohort. Am J Hypertens 2009;22:1235–41
    1. Waddell TK, Dart AM, Medley TL, et al. Carotid pressure is a better predictor of coronary artery disease severity than brachial pressure. Hypertension 2001;38:927–31
    1. Vlachopoulos C, Aznaouridis K, O'Rourke MF, et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010;31:1865–71
    1. Wang KL, Cheng HM, Sung SH, et al. Wave reflection and arterial stiffness in the prediction of 15-year all-cause and cardiovascular mortalities: a community-based study. Hypertension 2010;55:799–805
    1. Nguyen TT, Wang JJ, Sharrett AR, et al. Relationship of retinal vascular caliber with diabetes and retinopathy: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2008;31:544–9
    1. Pose-Reino A, Gomez-Ulla F, Hayik B, et al. Computerized measurement of retinal blood vessel calibre: description, validation and use to determine the influence of ageing and hypertension. J Hypertens 2005;23:843–50
    1. Ikram MK, de Jong FJ, Vingerling JR, et al. Are retinal arteriolar or venular diameters associated with markers for cardiovascular disorders? The Rotterdam Study. Invest Ophthalmol Vis Sci 2004;45:2129–34
    1. Hubbard LD, Brothers RJ, King WN, et al. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 1999;106:2269–80
    1. Tanabe Y, Kawasaki R, Wang JJ, et al. Retinal arteriolar narrowing predicts 5-year risk of hypertension in Japanese people: the Funagata study. Microcirculation 2010;17:94–102
    1. Tikellis G, Arnett DK, Skelton TN, et al. Retinal arteriolar narrowing and left ventricular hypertrophy in African Americans. The Atherosclerosis Risk in Communities (ARIC) study. Am J Hypertens 2008;21:352–9
    1. Yatsuya H, Folsom AR, Wong TY, et al. Retinal microvascular abnormalities and risk of lacunar stroke: Atherosclerosis Risk in Communities Study. Stroke 2010;41:1349–55
    1. Wong TY, Klein R, Sharrett AR, et al. Retinal arteriolar narrowing and risk of coronary heart disease in men and women The Atherosclerosis Risk in Communities Study. JAMA 2002;287:1153–9
    1. McGeechan K, Liew G, Macaskill P, et al. Meta-analysis: retinal vessel caliber and risk for coronary heart disease. Ann Intern Med 2009;151:404–13
    1. van Hecke MV, Dekker JM, Nijpels G, et al. Are retinal microvascular abnormalities associated with large artery endothelial dysfunction and intima-media thickness? The Hoorn Study. Clin Sci (Lond) 2006;110:597–604
    1. Sabanayagam C, Tai ES, Shankar A, et al. Retinal arteriolar narrowing increases the likelihood of chronic kidney disease in hypertension. J Hypertens 2009;27:2209–17
    1. Sabanayagam C, Shankar A, Klein BE, et al. Bidirectional association of retinal vessel diameters and estimated GFR decline: the Beaver Dam CKD Study. Am J Kidney Dis 2011;57:682–91
    1. Cuspidi C, Meani S, Salerno M, et al. Retinal microvascular changes and target organ damage in untreated essential hypertensives. J Hypertens 2004;22:2095–102
    1. Masaidi M, Cuspidi C, Giudici V, et al. Is retinal arteriolar-venular ratio associated with cardiac and extracardiac organ damage in essential hypertension? J Hypertens 2009;27:1277–83
    1. Garcia-Ortiz L, Recio-Rodriguez JI, Parra-Sanchez J, et al. A new tool to assess retinal vessel caliber. Reliability and validity of measures and their relationship with cardiovascular risk. J Hypertens 2012;30:770–7
    1. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840–4
    1. Redon J, Oliva MR, Tormos C, et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003;41:1096–101
    1. Lokuta AJ, Maertz NA, Meethal SV, et al. Increased nitration of sarcoplasmic reticulum Ca2+-ATPase in human heart failure. Circulation 2005;111:988–95
    1. Mihm MJ, Coyle CM, Schanbacher BL, et al. Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res 2001;49:798–807
    1. Wang W, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 2002;53:165–74
    1. Pesse B, Levrand S, Feihl F, et al. Peroxynitrite activates ERK via Raf-1 and MEK, independently from EGF receptor and p21Ras in H9C2 cardiomyocytes. J Mol Cell Cardiol 2005;38:765–75
    1. Liaudet L, Szabo E, Timashpolsky L, et al. Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences. Br J Pharmacol 2001;133:1424–30
    1. Levrand S, Pesse B, Feihl F, et al. Peroxynitrite is a potent inhibitor of NF-{kappa}B activation triggered by inflammatory stimuli in cardiac and endothelial cell lines. J Biol Chem 2005;280:34878–87
    1. Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011;478:103–9
    1. Bustelo XR. The VAV family of signal transduction molecules. Crit Rev Oncog 1996;7:65–88
    1. Sauzeau V, Jerkic M, Lopez-Novoa JM, et al. Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice. Mol Biol Cell 2007;18:943–52
    1. Sauzeau V, Sevilla MA, Montero MJ, et al. The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells. J Clin Invest 2010;120:315–30
    1. Sauzeau V, Sevilla MA, Rivas-Elena JV, et al. Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction. Nat Med 2006;12:841–5
    1. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191–4
    1. O'Brien E, Asmar R, Beilin L, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005;23:697–701
    1. Coca A, Bertomeu V, Dalfo A, et al. Blood pressure self measurement: Spanish consensus document. Nefrologia 2007;27:139–53
    1. O'Brien E, Petrie J, Littler W, et al. The British Hypertension Society protocol for the evaluation of automated and semi-automated blood pressure measuring devices with special reference to ambulatory systems. J Hypertens 1990;8:607–19
    1. Li Y, Wang JG, Dolan E, et al. Ambulatory arterial stiffness index derived from 24-hour ambulatory blood pressure monitoring. Hypertension 2006;47:359–64
    1. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–12
    1. Okin PM, Roman MJ, Devereux RB, et al. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995;25:417–23
    1. Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 2012;30:445–8
    1. Gomez-Marcos MA, Recio-Rodriguez JI, Patino-Alonso MC, et al. Protocol for measuring carotid intima-media thickness that best correlates with cardiovascular risk and target organ damage. Am J Hypertens 2012;25:955–61
    1. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19
    1. Tornavaca O, Pascual G, Barreiro ML, et al. Kidney androgen-regulated protein transgenic mice show hypertension and renal alterations mediated by oxidative stress. Circulation 2009;119:1908–17
    1. Perez-Rivero G, Ruiz-Torres MP, Diez-Marques ML, et al. Telomerase deficiency promotes oxidative stress by reducing catalase activity. Free Radic Biol Med 2008;45:1243–51

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi